VYNE Therapeutics Q3 net loss narrows, strategic review ongoing

Reuters11-06

VYNE <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss narrows, strategic review ongoing

Overview

VYNE Q3 net loss decreases compared to last year
Company progressing with strategic review to maximize shareholder value

Outlook

VYNE is conducting a strategic review to explore options like partnerships or mergers
Company expects cash runway to last into the first half of 2027
VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical hold

Result Drivers

STRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactions
COST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$169,000
Q3 Net Income		-$7.28 mln
Q3 EPS from Cont Ops		-$0.17

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vyne Therapeutics Inc is $3.25, about 89.6% above its November 5 closing price of $0.34

Press Release: ID:nGNXbBrRvS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581093260?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581093260","market":"us","top_or_hot":-1,"title":"VYNE Therapeutics Q3 net loss narrows, strategic review ongoing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>VYNE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows, strategic review ongoing</title></head><body><p><span>Overview</span></p><ul><li><p>VYNE Q3 net loss decreases compared to last year</p></li><li><p>Company progressing with strategic review to maximize shareholder value</p></li></ul><p><span>Outlook</span></p><ul><li><p>VYNE is conducting a strategic review to explore options like partnerships or mergers</p></li><li><p>Company expects cash runway to last into the first half of 2027</p></li><li><p>VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical hold</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>STRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactions</p></li><li><p>COST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$169,000</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$7.28 mln</p></td><td></td></tr><tr><td><p>Q3 EPS from Cont Ops</p></td><td></td><td><p>-$0.17</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vyne Therapeutics Inc is $3.25, about 89.6% above its November 5 closing price of $0.34</p></li></ul><p>Press Release: <span>ID:nGNXbBrRvS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VYNE Therapeutics Q3 net loss narrows, strategic review ongoing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVYNE Therapeutics Q3 net loss narrows, strategic review ongoing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>VYNE <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows, strategic review ongoing</title></head><body><p><span>Overview</span></p><ul><li><p>VYNE Q3 net loss decreases compared to last year</p></li><li><p>Company progressing with strategic review to maximize shareholder value</p></li></ul><p><span>Outlook</span></p><ul><li><p>VYNE is conducting a strategic review to explore options like partnerships or mergers</p></li><li><p>Company expects cash runway to last into the first half of 2027</p></li><li><p>VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical hold</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>STRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactions</p></li><li><p>COST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$169,000</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$7.28 mln</p></td><td></td></tr><tr><td><p>Q3 EPS from Cont Ops</p></td><td></td><td><p>-$0.17</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vyne Therapeutics Inc is $3.25, about 89.6% above its November 5 closing price of $0.34</p></li></ul><p>Press Release: <span>ID:nGNXbBrRvS</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VYNE","symbol_name":"VYNE Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0QN:1","article_id":"2581093260","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581093260","pubTimestamp":1762434439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"VYNE Therapeutics Q3 net loss narrows, strategic review ongoingOverviewVYNE Q3 net loss decreases compared to last yearCompany progressing with strategic review to maximize shareholder valueOutlookVYN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VYNE":"VYNE Therapeutics Inc.","BK4007":"制药"},"translate_title":"VYNE Therapeutics第三季度净亏损收窄，战略审查正在进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VYNE":0.9},"content_text":"VYNE Therapeutics Q3 net loss narrows, strategic review ongoingOverviewVYNE Q3 net loss decreases compared to last yearCompany progressing with strategic review to maximize shareholder valueOutlookVYNE is conducting a strategic review to explore options like partnerships or mergersCompany expects cash runway to last into the first half of 2027VYNE is conducting a 12-week toxicology study for VYN202 to lift a clinical holdResult DriversSTRATEGIC REVIEW - Co is evaluating strategic alternatives to maximize shareholder value, including potential partnerships and transactionsCOST REDUCTIONS - Co implemented cost reductions to extend cash runway into first half of 2027Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$169,000Q3 Net Income-$7.28 mlnQ3 EPS from Cont Ops-$0.17Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Vyne Therapeutics Inc is $3.25, about 89.6% above its November 5 closing price of $0.34Press Release: ID:nGNXbBrRvSFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581093260","isCrawlerRequest":true}